Potassium-Competitive Acid Blockers: A New Era in Acid Suppression Therapy

INTRODUCTION TO P-CABS

P-CABs function by selectively inhibiting the hydrogen-potassium ATPase (H⁺/K⁺ ATPase) enzyme, the final step in gastric acid secretion, which is primarily responsible for producing hydrochloric acid in the stomach.² Unlike PPIs, which require activation through acidic environments to become effective, P-CABs act in a more direct, reversible manner by competing with potassium ions at the binding site of the ATPase, preventing the enzyme from pumping protons into the stomach lumen.^2,3 This difference in mechanism gives P-CABs a unique profile with several potential benefits over PPIs, such as faster onset of action and sustained acid suppression. Selecting the most suitable P-CAB requires careful consideration of its impact on Cytochrome P450 enzyme activity, formulation type, and potential interactions with food.³

PHARMACOLOGICAL PROFILE AND MECHANISM OF ACTION

The primary characteristic that distinguishes P-CABs from traditional PPIs is their mode of action. PPIs are prodrugs that must undergo activation in the acidic environment of the parietal cell canaliculus, whereas P-CABs directly interact with the H⁺/K⁺ ATPase enzyme. This mechanism allows P-CABs to provide rapid acid suppression, with peak effects occurring much sooner than PPIs, which typically take several hours to activate and reach their maximum effect.⁴

Recent studies have demonstrated that P-CABs bind to the proton pump in a potassium-competitive manner, leading to a more predictable and potent inhibition of gastric acid secretion. Importantly, this interaction is reversible, which may reduce the risk of long-term side effects associated with sustained acid suppression, such as gastric atrophy or bacterial overgrowth.⁵

CLINICAL APPLICATIONS AND EFFICACY

P-CABs have shown considerable promise in the treatment of acid-related disorders, including gastrointestinal diseases such as GERD, peptic ulcer disease (PUD), Helicobacter pylori eradication (H. pylori), Non-steroidal anti-inflammatory drugs (NSAID)-induced ulcers, esophagitis, and Zollinger– Ellison syndrome.

In GERD, PCABs such as vonoprazan and tegoprazan have demonstrated superior or non-inferior healing rates compared to PPIs, particularly in patients with severe erosive esophagitis (Los Angeles Grade C/D).^6,7 Vonoprazan is also effective in non-erosive reflux disease, where it has been shown to significantly improve symptom control and quality of life.

In PUD, PCABs are as effective as PPIs in healing both gastric and duodenal ulcers. PCABs have proven to be effective components of H. pylori eradication regimens, showing higher eradication rates when substituted for PPIs in triple or quadruple therapy.^8,9

PCABs are effective in promoting faster healing of ulcers following endoscopic procedures such as endoscopic submucosal dissection.¹⁰ In addition, they are effective in preventing and managing NSAID-associated ulcers due to their potent and sustained acid suppression.¹¹

While data on Zollinger–Ellison syndrome and other hypersecretory conditions remain limited, the potent acid suppression offered by PCABs suggests a potential role in these high-acid pathologies as well. Overall, PCABs are emerging as a promising alternative or adjunct to PPIs, offering clinical benefits across a wide range of acid-related disorders. Ongoing studies will further define their long-term safety and comparative efficacy across different populations and disease severities.

SAFETY PROFILE

One of the major concerns with long-term PPI use is the potential for side effects, including nutrient deficiencies (e.g., Vitamin B12 and magnesium), bone fractures, and increased risk of infections such as Clostridium difficile.¹² P-CABs, however, have shown a more favourable safety profile in both short- and long-term use. Studies indicate that P-CABs do not interfere with the absorption of Vitamin B12 or magnesium to the same extent as PPIs, and their reversible action may potentially reduce the risk of gastric atrophy. Moreover, the effect of the long-term use of P-CABs on the gut microbiota, which is a problem commonly associated with PPIs, needs to be explored.^13-15

FUTURE DIRECTIONS AND ONGOING RESEARCH

While the benefits of P-CABs are clear, ongoing research is exploring their long-term efficacy and safety, especially in chronic conditions such as GERD and peptic ulcers. Several studies are investigating the potential for P-CABs to be used as first-line therapy for these conditions, with some preliminary results suggesting that they could offer better long-term control with fewer side effects than PPIs. In addition, the role of P-CABs in combination therapies for H. pylori eradication is a topic of active investigation. Researchers are exploring the potential for P-CABs to enhance the efficacy of treatment regimens, especially in regions with high antibiotic resistance.

Despite the promising clinical utility of PCABs, several important gaps remain in the current literature. There is very limited published data on their use in Zollinger– Ellison syndrome or other hypersecretory conditions, with no large randomised controlled trials available to date. Similarly, while vonoprazan and tegoprazan have been more extensively studied, other agents such as revaprazan, fexuprazan, and keverprazan have sparse data, especially in non-Asian populations, and virtually no published evidence regarding their efficacy in hypersecretory states. In addition, the long-term safety of PCABs remains to be fully understood, particularly concerning risks related to sustained acid suppression such as hypergastrinemia, gastric mucosal alterations, Clostridioides difficile infection, and nutrient malabsorption.

Finally, head-to-head comparative trials between different PCABs are currently lacking, which limits our ability to discern the superiority or differences in efficacy and safety profiles among agents within this class. As clinicians and researchers continue to explore the potential of P-CABs, they may pave the way for a new era in the treatment of acid-related diseases.